Israel Cannabis Law

Israel has been a global center for cannabis research and medical cannabis innovation since the 1960s, when Professor Raphael Mechoulam identified THC and catalyzed modern cannabinoid science. The Israeli Medical Cannabis Agency (IMCA) administers a sophisticated G.A.P., G.M.P. quality framework for licensed producers. Israel's medical cannabis export market, formalized in 2021, has made it a significant supplier to European and other international markets.

Israel's cannabis industry is characterized by strong research and development capabilities, with Hebrew University and Volcani Center researchers producing cannabis innovation that is globally influential. The Oasis model — vertical integration from cultivation through pharmaceutical formulation — is a uniquely Israeli contribution to the industry. Israeli cannabis companies have attracted substantial US and European investment.

Bob Hoban has the most extensive advisory experience in the Israeli market among US cannabis attorneys, having advised US investors, Israeli licensed producers, and international pharmaceutical companies on Israeli market strategy, IMCA licensing, export compliance, and M&A. Key advisory areas include IMCA G.A.P./G.M.P. licensing, Israeli export framework compliance, US-Israel investment structures, Tel Aviv Stock Exchange (TASE) listed cannabis company M&A, and the interface between Israeli cannabis law and US Controlled Substances Act obligations for US-invested entities.